Offering largest line of Covid 19 tests, Global WholeHealth Partners Corp (OTCMKTS:GWHP) said that Antibody IgG/IgM tests can detect the current identified SARS-CoV-2 viruses.The firm shipped its first shipment of over 20,000 tests to Salud Previa of Tijuana.
Brazilian, UK and South African strains have a number of mutations, reflected in S gene, which encodes spike protein, which the firm understands for staying ahead of the virus.
The company recognises there is a vital need for quicker testing and also results for fighting Covid. The firm is also aware that such results can be assessed by Front-Line Healthcare Worker for stopping the spread of the disease.
Global WholHealth Partners also gives advanced technology harnessing In-vitro Diagnostic Real-Time PCR Machines for detecting SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood. It has initiated fight against terminal diseases like ZIKA, Ebola, Malaria, Dengue,Influenza and Tuberculosis and other vector borne diseases with FDA Certificate of Exportability. Founded on March 7, 2013 and headquartered in San Clemente, CA, GWHP develops as well as manufactures IVD tests for OTC as well as diagnostic point-of-care (POC) test kits.
Offering 56 products that are FDA approved, many are approved for OTC usage and 15 POC products approved by the CLIA WAIVED FDA.
On Thursday, GWHP stock went up 13.65% at $0.38 with more than 837k shares, compared to its average volume of 179k shares. The stock had moved within a range of $0.3323 – 0.3890 after opening the trade at $0.35. Over the past 52-week, the stock has been trading within a range of $0.2950 – 2.1700.